Ayala Pharmaceuticals Inc (AYLA) Peer Comparison
$0.50
$0.00 (0.00%)As on 27-Jan-2023 09:30EDT
Market cap
$8 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Edit
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
Market cap ($ Mln) |
8 | 1,219 | 521 | 300 |
Revenue ($ Mln) |
2 | -- | 68 | 20 |
Net Profit ($ Mln) |
-30.42 | -61.64 | -29.04 | -176.65 |
Net Margin (%) |
-1,755.34 | -8,110.13 | -42.56 | -1,287.59 |
RoE (%) |
-184.49 | -33.13 | -88.28 | -- |
Price to Earnings |
-- | -- | -- | -- |
Price-To-Book |
1.02 | 7.04 | 17.96 | 2.39 |
Income Statement ($ Mln)
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Operating Revenue
|
3.51 | 0.00 | 38.87 | 24.54 |
|
Cost of Revenue
|
3.51 | -- | 4.74 | 1.53 |
|
Gross Profit
|
-3.51 | -- | 34.14 | 23.01 |
|
Operating Expenses
|
39.22 | 42.52 | 87.11 | 119.67 |
|
Operating Profit (EBIT)
|
-39.22 | -42.52 | -49.55 | -96.66 |
|
Other Income
|
-- | -0.10 | 0.26 | -0.27 |
|
Profit before Tax
|
-39.48 | -42.31 | -53.34 | -100.66 |
|
Provision for Tax
|
-0.78 | 0.00 | -- | -- |
|
Profit after Tax (Net Income)
|
-40.25 | -42.31 | -53.34 | -100.66 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-40.25 | -42.31 | -53.34 | -100.66 |
Liabilities ($ Mln)
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
34.16 | 214.69 | 45.87 | 99.54 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
0.50 | 0.00 | 40.74 | 94.28 |
|
Current Liabilities
|
6.47 | 10.09 | 18.73 | 28.80 |
|
Total Liabilities
|
1.39 | 224.79 | 105.34 | 222.62 |
Assets ($ Mln)
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Non-Current Assets
|
-38.35 | 3.48 | 0.61 | 7.37 |
|
Current Assets
|
39.74 | 221.30 | 104.74 | 215.25 |
|
Total Assets
|
34.66 | 224.79 | 105.34 | 222.62 |
|
Total Debt*
|
0.55 | -- | 14.14 | 92.73 |
|
Net Current Assets
|
33.27 | 211.21 | 86.01 | 186.45 |
Cashflow ($ Mln)
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-38.36 | -39.76 | -57.26 | -89.37 |
|
Cash Flow from Investing Activities
|
-0.01 | -129.27 | -16.87 | -1.49 |
|
Cash from Financing Activities
|
33.33 | 160.99 | 82.90 | 91.64 |
|
Net Cash Inflow / Outflow
|
25.56 | -8.04 | 8.78 | 0.79 |
Ratios
Profitability Ratios
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
ROCE (%)
|
-110.12 | -58.00 | -111.94 | -53.03 |
|
ROE (%)
|
-110.96 | -58.00 | -131.44 | -70.34 |
|
ROA (%)
|
-170.51 | -26.14 | -61.93 | -47.87 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-1,148.15 | 42,738.38 | -136.32 | -414.76 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.05 | -- | 5.46 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
-33.53 | -137.26 | -49.90 | -42.74 |
|
EPS Growth (%)
|
0.05 | 0.85 | 0.05 | -0.41 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Price / Earnings
|
-2.96 | -8.97 | -2.90 | -4.75 |
|
Price / Book Value
|
3.49 | 1.77 | 3.37 | 4.80 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-2.01 | -3.86 | -1.18 | -3.90 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.01 | -- | 0.40 | 0.93 |
|
Short term debt to equity ratio
|
-- | -- | 0.00 | 0.01 |
|
Current Ratio
|
6.14 | 21.93 | 5.59 | 7.47 |
|
Quick Ratio
|
-- | -- | 5.50 | 7.26 |
|
Interest Coverage
|
-157.81 | -133.74 | -12.25 | -25.96 |
Operating Efficiency Ratios
| Ayala Pharmaceuticals Inc (AYLA) | Imago Biosciences Inc (IMGO) | AVEO Pharmaceuticals (AVEO) | Oyster Point Pharma (OYST) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | -- | 25.24 | 27.12 |
|
Asset Turnover
|
0.15 | 0.00 | 0.45 | 0.12 |
|
Receivable days
|
35.47 | -- | 51.71 | 99.07 |
|
Inventory Days
|
-- | -- | 127.69 | 1,457.65 |
|
Payable days
|
361.50 | -- | 234.86 | 1,050.84 |
|
Cash Conversion Cycle
|
-- | -- | -55.46 | 505.88 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
